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tains information on medical status, presence and extent
of objectively diagnosed thromboembolic disease, treat-
ments, and details of filter placement.
Patients receive an annual reminder letter to schedule
a follow-up appointment, which includes physical exami-
nation, abdominal radiography, and lower extremity vein
and inferior vena cava duplex ultrasound examinations.
The follow-up record includes physical examination of the
extremities, medical history since filter placement, recur-
rence of pulmonary embolism (PE), and objective tests for
filter patency, DVT, chronic venous insufficiency, and sta-
bility of the filter. The rate of follow-up for the entire reg-
istry is 54%, and the mean length of follow-up exceeds 5
years. These data are maintained in a 4th Dimension data-
base, Version 6.0 for the Macintosh (4D Inc, San Jose,
Calif).
Patients with acute DVT or PE at the time of filter
placement comprise the study cohort. Information on
anticoagulation was limited to the type of agent and the
time it was used relative to filter placement. These cases
were stratified according to the use of anticoagulants
either during the postprocedural period or during subse-
quent follow-up and analyzed on the basis of subsequent
complications. Four outcomes were evaluated; new DVT,
PE, caval occlusion, or venous ulceration. New DVT was
diagnosed on the basis of color-flow Doppler-duplex stud-
ies. Both extremities were scanned from above the groin
to the ankle. Lack of compressibility or visualization of
thrombus were the criteria for a positive diagnosis.
Thrombus was characterized as acute or chronic and
whether it was a new abnormality or a previous finding.
Information regarding new PE was based on patient
reports or diagnostic studies performed during the prior
interval. All reports of PE, whether reported by the
Vena cava filtration is standard treatment for patients
with thromboembolic disease who are unable to receive
anticoagulants or are at such risk from pulmonary
embolism that additional protection is required. Because
the filter has no effect on the underlying venous disease,
anticoagulants are recommended in conjunction with the
filter whenever possible to prevent recurrent thromboem-
bolism and postthrombotic sequelae. The outcomes for
patients who cannot receive anticoagulants remains uncer-
tain, although a recent study of filter use in connection
with heparin suggested that filter placement could increase
the risk of recurrent deep venous thrombosis (DVT).1
Early in our experience we studied the importance of anti-
coagulation and were unable to find a difference in the
outcomes of more than 100 cases.2 This review extends
that experience to more than 1024 patients who had filters
placed in the presence of acute thrombosis and were mon-
itored for 3053 person-years.
METHODS
The Michigan Filter Registry has been maintained
continuously since 1972 and contains prospectively col-
lected data for 2109 consecutive patients treated by the
senior author over a 28-year period. The entry record con-
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vena cava filters
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Background: Patients with venous thromboembolic disease are treated with anticoagulation or vena cava filter place-
ment to prevent pulmonary embolism. A recent report suggested that filter placement may increase the risk of recur-
rent deep venous thrombosis (DVT) and prompted a review of our experience.
Methods: Prospectively collected data on 2109 consecutive patients receiving filters were evaluated for recurrent throm-
boembolism, vena cava occlusion, or venous stasis ulceration. Outcomes were stratified and analyzed according to the
use of anticoagulants at the time of insertion and at follow-up. Incidence rates were also compared with reports in the
literature.
Results: Of 1191 patients with DVT at filter placement, complete follow-up data at a mean of 9 years were available
for 465. Recurrent DVT was found in 12% of the 241 patients who were given anticoagulants and 15% of the 224 who
were not (P > .05). We also failed to find a significant association between the use of anticoagulation and the incidence
of pulmonary embolism (2%), stasis ulceration (2%), and vena cava occlusion (0.0).
Conclusions: Recurrent DVT in patients with existing thromboembolic disease is not an unexpected event, which, in our
experience, is not associated with anticoagulant or filter use. Anticoagulation should be used when possible to treat
existing DVT to reduce thrombus progression and potentially to reduce subsequent complications but does not seem
to reduce the rate of recurrent DVT. Rates of recurrent thromboembolism were consistently less than the 20% to 50%
reported in the literature. (J Vasc Surg 2001;33:510-4.)
patient or documented by objective testing, were treated
as confirmed. Filter or caval occlusion was diagnosed by
Doppler-duplex ultrasound scanning. The cava was con-
sidered occluded if the filter could not be visualized and
Doppler signals were absent. 
Reports of occlusion on the basis of vena cavograms or
computed tomography scans were also included in this
category. Venous ulceration was documented with obser-
vation at the time of the lower extremity study. Findings
of edema and use of support stockings were based on
observation during the lower extremity study and patient
reports.
Statistical analyses were conducted with Systat version
5.0 for the Macintosh (Systat, Evanston, Ill) and SAS
V.6.12 (SAS Institute, Cary, NC). Continuous data were
compared with the Student t test, whereas the Fisher exact
test or likelihood ratio χ2 tests were used with dichoto-
mous outcomes. We evaluated the null hypothesis of no
association between the use of anticoagulants after filter
placement and the incidence of new thromboembolic
events or vena cava occlusion. Because four comparisons
were involved in the primary analysis, the P value was
adjusted with a Bonferroni correction, with P less than
.0125 being considered significant. Additional exploratory
analyses were conducted to generate new research ques-
tions regarding the association between underlying dis-
ease, indication for filter placement, and the use of
anticoagulation. The P value was not corrected for these
comparisons. Survival analyses with life-table methods and
Kaplan-Meier plots were generated, and group compar-
isons were made with the log-rank test.
RESULTS
A cohort of 1191 patients with acute DVT at the time
of filter placement was identified. It represented 54% of
the database. Sixty-seven of the 1191 patients were given
anticoagulants at some time during the initial hospitaliza-
tion, but the timing relative to filter placement was
unknown, leaving 1124 cases included in the analyses.
Table I summarizes the demographic information show-
ing that the groups were comparable with respect to age
and sex but showed a clinically important difference in
mortality rates and length of survival that favored those
who were given anticoagulants. Table II describes the
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related procedural events that are similar for the two
groups. Tables III and IV report the indications for filter
placement and primary diagnoses for each group.
Data were complete for 465 patients who had at least
one follow-up appointment. The patient groups differed
in that those without follow-up had a higher incidence of
cancer as the primary diagnosis. This probably explains the
higher mortality rate, shorter survival time, and higher
rate of PE-related death (Table V). The incidence of new
DVT in this cohort was 13.3%. PE was suspected or con-
firmed in 3%, and caval occlusion occurred in 0.4%. Mean
survival was 57.7 months, 95% CI (53.8, 61.3). Survival is
depicted in Fig 1.
Among those who had follow-up, 241 were given
anticoagulants and 224 were not. We failed to reject the
null hypothesis for the major outcomes of interest; for new
PE, DVT, cava occlusion, or venous ulceration, however,
the survival rate was different (Fig 1, Table V). Specifically,
among those patients who were examined for follow-up,
the difference in the incidence of new DVT (3%, P = .35)
and PE (2%, P = .16) failed to reach statistical significance,
Table I. Demographic data for filter patients with
thromboembolic disease
Anticoagulation No anticoagulation
(n = 487) (n = 637)
Age (y) 54 (12-93) 58 (19-93)*
Male 253 (52%) 333 (48%)
Mortality 167 (34%) 302 (48%)
Survival 59 mo 47 mo*
Follow-up
All cases 241 (50%) 224 (35%)
Survived 1 year 206 (64%) 178 (52%)
*P < .05.
Table II. Filter placement details by percent in each
category
Anticoagulant No anticoagulant
(n = 487) (n = 637)
Number of filters
1 100% 99.9%
2 0 .1%
Inserted
Radiology 80% 74%
Surgery 20% 26%
Method
Percutaneous 80% 72%
Surgical 20% 28%
Type of filter
PSGF 32% 20%
SGF 22% 33%
TGF 44% 45%
Other 2% 2%
Filter location
Infrarenal 92.1% 91.7%
Suprarenal 7.5% 7.6%
Superior vena cava 0.3% 0.2%
Misplaced 1% 0.5%
Route
Missing 3% 2%
Jugular 28% 11%
Femoral 67% 81%
Other 2% 1%
Insertion problems
Asymmetry 2.6% 1.7%
Tilt 0.2% 1%
Crossed legs 0.2% 0.2%
Incomplete opening 0.8% 0.2%
Placement morbidity
Leg swelling 0 0.8%
Hematoma 2% 1%
Infection 0 0.3%
Bleeding 0.8% 0.5%
PSGF, Percutaneous stainless steel Greenfield filter; SGF, stainless steel
Greenfield filter; TGF, titanium Greenfield filter.
and the incidence of inferior vena cava occlusion was iden-
tical for the two groups at less than 1%. Fig 2 depicts the
lack of association between new DVT and anticoagulant
use (P = .36 log-rank test). Lower extremity edema was
similar in the two groups, but twice as many patients wore
support stockings to control symptoms of venous insuffi-
ciency in the no-anticoagulation group (P = .006). This
suggests that anticoagulation may modify the long-term
sequelae of DVT. In subsequent follow-up visits, antico-
agulation was used more often in those who had been
given anticoagulants initially after filter placement, and
this group experienced twice the number of anticoagulant
complications while receiving long-term anticoagulation
than those who had not been given anticoagulants initially
(Table VI). Patients with a history of thromboembolism
were given anticoagulants more frequently than those
without (P < .0001, Table III).
As expected, contraindication to anticoagulation
accounted for a greater percentage of cases in the no-
anticoagulation group (P < .0001, Table IV). No distinc-
tion between relative and absolute contraindication was
made. With careful evaluation and follow-up, it is possible
to safely give anticoagulants to most patients once the con-
traindication has resolved. This may especially be true where
the contraindications were relative or weak. Sixty-one
patients were given anticoagulants after filter placement in
the group who had received anticoagulation, and 81 of the
patients in the no-anticoagulation group were given antico-
agulants during 1 or more years after filter placement.
DISCUSSION
This study is based on data from a registry that has
inherent limitations; detailed patient information regard-
ing level and length of anticoagulation is not available, the
groups are not randomized and the rate of follow-up is
low (52%-64%). Methods of testing for recurrent DVT
changed over time from duplex ultrasound scanning to
color flow Doppler scanning. We do not track prothrom-
bin time, international normalized ratio, or activated par-
tial thromboplastin time values, so it is not possible to
comment on the patients’ level of anticoagulation, only
whether it was ordered. This limits the strength of our
findings. However, these data were collected prospectively
from consecutive cases, and the numbers are large. These
factors must be considered when weighing the validity of
our conclusions. With respect to recurrent DVT and PE,
cava occlusion and stasis ulceration, the differences
between the groups failed to reach statistical significance;
however, a post hoc analysis found the power of the study
to detect a difference was low. More important, however,
the differences were clinically insignificant. In this patient
cohort, the clinical difference is probably the more useful,
allowing physicians to determine the importance to their
own practice. Our findings suggest that it is the underly-
ing thrombotic risk that is associated with recurrent
thromboembolic events and sequelae rather than the pres-
ence of the filter.
In a previous animal study, Greenfield filters were
placed in mongrel dogs and filled with autologous throm-
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Table III. Primary underlying diagnosis related to use of
anticoagulation
Anticoagulation No anticoagulation 
(n = 487) (n = 637)
Thromboembolism 32% 20%*
Malignancy 20% 27%*
Trauma 10% 8%
Cardiac 4% 5%
Pulmonary 2% 2%
Surgery 24% 26%
Other 8% 12%
*P value < .05.
Table IV. Indications for filter placement related to use
of anticoagulation
Anticoagulation No anticoagulation
(n = 487) (n = 637)
Anticoagulant 23% 62%
contraindication
Anticoagulant 17% 18%
complication
Recurrent PE 15% 3%
Prophylaxis 40% 14%
Embolectomy 1% 0.4%
Missing 4% 2.6%
Table V. Comparison of patients stratified by use of anticoagulants and follow-up
Anticoagulation No anticoagulation
Follow-up No follow-up Follow-up No follow-up
No. 263 292 225 418
Male sex 54% 53% 48% 54%
Mean age in years 53.2 55.9 55.4 57.4
Diagnosis of cancer 10.4% 28.5% 13.8% 33.3%
Mean survival in mo 75.6 32.7 75.3 38.4
Mortality 14% 56% 20% 61%
PE-related morbidity 0 1% 0 1%
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bus. The animals were randomly assigned to receive
heparin, warfarin (Coumadin), or no anticoagulants.
Logistic regression analyses demonstrated that thrombus
resolution was associated with the initial thrombus burden
and elapsed time from filter placement, not the use of
anticoagulants.3 These differences were found in spite of
the presence of the filter in all animals.
Meissner et al4 reached the same conclusion in a clin-
ical study where the only risk factor significantly associated
with recurrent DVT was the extent of thrombus burden at
the initial thromboembolic event. Regression analysis
showed that in a model including age, diagnosis, and anti-
coagulation, the only factor associated with the new DVT
was the underlying diagnosis (P < .02). In an earlier analy-
sis of our data on anticoagulation in patients with filters,
nine new thromboembolic events occurred, and six were
among those who were given anticoagulants, suggesting
that there was some inherent difference among the groups
that resulted in recurrent thromboembolism other than
the use of anticoagulants.2
The literature regarding vena cava filters and the use of
anticoagulation is conflicted. It supports the utility of anti-
coagulation for treating underlying venous disease among
patients with filters, but it also indicates that anticoagula-
tion is not associated with statistically significant differ-
ences in recurrence of thromboembolic events or sequelae
Fig 1. There was a difference in mortality rate that was associated with use of anticoagulation.
Fig 2. There was no difference in timing of new DVT that was associated with use of anticoagulation.
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of venous thromboembolism. Both Cugell5 and Harris et
al6 support the use of anticoagulation on the basis of the
assumption that it should lower the risk of recurrent
embolism or phlegmasia cerulea dolens in patients with fil-
ter placement, reinforcing the importance of continuing
to treat the underlying venous disease when possible.
However, Ortega et al7 and Jones et al8 failed to observe
this proposed benefit.
The incidence of recurrent thromboembolism in this
analysis is similar to estimates we reported in the past, sug-
gesting that the incidence does not change over time.2,9
However, for individual patients it declined and stabilized
after 24 months (Fig 2). DVT recurred in 12% or 15% of
patients, depending on whether anticoagulation was used,
which is similar to other series.10 Meissner et al4 studied
177 patients with DVT during a 7-year period and a
median follow-up of 9 months and found that recurrent
thrombotic events (either rethrombosis, extension, or new
DVT) occurred in 52% of patients. This was true in spite
of the fact that between 59% and 88% of patients were
given anticoagulants and were not given filters.
Mortality rates differed among the groups, favoring
those who received anticoagulation, which may be due to
an important difference in the underlying diagnosis, with
the no-anticoagulation group having statistically signifi-
cantly more patients with cancer than those who were
given anticoagulants (Table V). The difference in survival
rates remained significantly different when we controlled
for both cancer and anticoagulant use. Patients without
malignancy continued to demonstrate longer survival rel-
ative to patients with cancer. Anticoagulation appears to
be associated with improved survival rates among the non-
cancer group but not among those with cancer. In a full
logistic regression model younger age (P = .005), antico-
agulation (P = .0375) and the status of the thromboem-
bolic event (P = .001) were associated with superior
survival rates. This finding requires further investigation.
A group of French investigators studied the interac-
tion of filters and anticoagulants from an alternative per-
spective examining the effect of filter placement in addi-
tion to anticoagulation in patients diagnosed with DVT or
PE.1 These patients represent a very different population
than our own. The authors reported that in spite of failing
to enroll sufficient numbers of patients, they were still able
to demonstrate a statistically significant benefit of the fil-
ter with respect to preventing new PE within the first 12
days. However, when they looked at the incidence of DVT
2 years later, they found that the rate was significantly
higher in the patients with filters and concluded that the
initial benefit of the filter was offset by this increased inci-
dence of DVT at 2 years. Unfortunately, there was not suf-
ficient information to evaluate their findings, especially
with respect to continued use of anticoagulation, underly-
ing disease, patency of the vena cava, and the type of filter
that was used.
The decision to use anticoagulation in addition to a
vena cava filter and the duration of this therapy should be
based on an individual risk/benefit assessment, not from
concern for filter-induced thrombosis. After all, the trade-
off between a fatal PE and a recurrent DVT is not difficult
to assess. Physicians should not hesitate to follow their
customary patterns for use of vena cava filters or feel a
need to prolong anticoagulant use out of concern for a
potential increased recurrence of DVT because there is no
evidence to support that assumption.
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Please see related commentary by Dr John J. Ricotta
on page 657.
Table VI. Long-term results in patients who had follow-
up stratified with anticoagulation at time of filter insertion
Anticoagulation No anticoagulation
(n = 241) (n = 224)
New DVT 12% 15%
Recurrent PE 4% 2%
IVC occlusion 0.4% 0.4%
Ulceration 4% 6%
Edema 56% 55%
Stockings 17% 34%*
Anticoagulation 61% 36%*
during follow-up
Anticoagulant 7% 3.6%
complication
*P value < .05.
IVC, Inferior vena cava.
